We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Invitation to the presentation of Calliditas´s interim report January - June 2024 PR Newswire STOCKHOLM, Aug. 5, 2024 STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the...
Invitation to the presentation of Calliditas´s interim report January - June 2024 PR Newswire STOCKHOLM, Aug. 5, 2024 STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the...
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT) (“Calliditas”) Chief Executive Officer, Renée Aguiar-Lucander, will participate in a panel during this...
Number of shares and votes in Calliditas Therapeutics PR Newswire STOCKHOLM, July 31, 2024 STOCKHOLM, July 31, 2024 /PRNewswire/ -- During July, the number of shares and votes in Calliditas...
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy PR Newswire STOCKHOLM, July 26, 2024 STOCKHOLM, July 26, 2024...
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy PR Newswire STOCKHOLM, July 26, 2024 STOCKHOLM, July 26, 2024...
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis PR Newswire STOCKHOLM, July 26, 2024 STOCKHOLM, July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics...
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis PR Newswire STOCKHOLM, July 26, 2024 STOCKHOLM, July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics...
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM, July 4, 2024 STOCKHOLM, July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ STOCKHOLM:...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions